OPT101 in Type 1 Diabetes Patients

A Phase 1b Study of OPT101 in Patients With Type 1 Diabetes

Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 1
• Intervention / Treatment: Drug: OPT101

• Study Type: Interventional
• Enrollment (Actual): 22
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Walnut Creek, California, United States, 94598
      • Diablo Clinical Research Center
  • Washington
    • Renton, Washington, United States, 98057
      • Rainier Clinical Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Able and willing to give informed consent for the trial
2. Male or female aged ≥18 years on the day of signing informed consent
3. Diagnosis of Type 1 diabetes (T1D) within the last 20 years
4. Is medically stable based on physical examination, medical history, laboratory results, and vital signs performed at screening
5. Women of childbearing potential must have a negative highly sensitive serum test (beta-human chorionic gonadotropin) at screening and a negative urine pregnancy test at the Visit 1 Day 1 prior to receiving the investigational product.

6. Women must agree to use one of the following methods of birth control for the duration of the clinical trial: systemic hormonal contraceptive (oral, injected, transdermal), intrauterine device, double barrier (e.g., cervical cap or diaphragm with condom or spermicide). Men with female partners must agree to use double barrier contraception, unless their partner is using systemic hormonal contraceptives or has an intrauterine device.

   -

Exclusion Criteria:

1. Is over the age of 60 years old
2. Currently has or had a history of malignancy
3. Has an immune deficiency syndrome (for example, severe combined immunodeficiency syndrome, T-cell deficiency syndromes, B-cell deficiency syndromes, or chronic granulomatous disease), or bone marrow or organ transplantation, or a disease associated with lymphopenia
4. Is currently receiving an immuno-modulatory treatment.
5. Patients with a history of venous and arterial thromboembolic events including, but not limited to, the following: deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, transient ischemic attack, or arterial insufficiency causing digital gangrene should be excluded. In addition, patients with recent immobilization or recent surgery, should be excluded. Patients with a history of abnormal prothrombotic laboratories such as congenital or inherited deficiency of antithrombin III, protein C, protein S, or confirmed diagnosis of antiphospholipid syndrome should also be excluded.
6. Has active infections, is prone to infections or has chronic, recurrent or opportunistic infectious disease, including but not limited to, Epstein-Barr virus (EBV), cytomegalovirus (CMV) chronic renal infection, chronic chest infection, sinusitis, recurrent urinary tract infection, Pneumocystis carinii, aspergillosis, latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis or an open, draining, or infected non-healing skin wound or ulcer
7. Has recent or active hepatitis A infection, current/chronic hepatitis B and hepatitis C infection, or HIV infection. Participants with immunity to hepatitis B from previous infection (defined as negative HBsAg, positive anti-HBc, and positive hepatitis B surface antibody [anti-HBs]) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti-HBs) may be eligible to participate.
8. Has a history of latent or active TB
9. Has received a live (attenuated) vaccine within the last 60 days, including patients who plan to receive live (attenuated) vaccines during the study or within 60 days after the final dose of study treatment.

10. Patients with clinically significant abnormal laboratory test values in screening blood samples. In particular patients with the following should be excluded:

    i. Patients with abnormal coagulation panel at screening such as abnormal PT or aPTT or fibrinogen ii. Abnormal liver function tests:

1. Liver enzyme abnormalities (except in the case of known Gilbert's syndrome) 2. AST or ALT ≥3x ULN and total bilirubin ≥2x ULN 3. AST or ALT ≥5x ULN 4. AST or ALT ≥3x ULN if associated with appearance or worsening of rash or hepatitis symptoms iii. Abnormal platelet counts (<150,000mcL or > 450,000mcL) iv. Abnormal white blood cell counts (<3mL or > 11mL) v. Abnormal eGFR (<50mg/dL or >1.10mg/dL) vi. Abnormal Factor VIII (> 160%) vii. Abnormal D-Dimer (> 500ng/mL FEU) 11. Patients planning to undergo elective procedures or surgeries at any time after signing the ICF through the follow-up visit.

12. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.

13. Recent history of bleeding or bleeding disorders or any condition whereby in the opinion of the treating investigator giving anti-coagulation during treatment would be contraindicated.

14. History of hypersensitivity to antihistamines. 15. Weight is over 250lbs. 16. Patients with active drug or alcohol abuse within 1 year prior to screening 17. Patient is participating in a clinical trial of another investigational drug or device, including patients who have participated in another study for a duration of 5 half-lives of the investigational agent.

18. Patient is a prisoner 19. Investigators could exclude patients with any medical condition, including, but not limited to, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal, or a psychiatric condition that, in the opinion of the Investigator, could compromise the participant's ability to participate in this study.

-

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: OPT101 1.1 mg/kg and Placebo; 9 subjects (6 investigational product:3 placebo)	Drug: OPT101; 15-mer peptide derived from the sequence of mouse CD154.
Other: OPT101 2.8 mg/kg and Placebo; 9 subjects (6 investigational product:3 placebo)	Drug: OPT101; 15-mer peptide derived from the sequence of mouse CD154.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Treatment related adverse events will be recorded and assessed by CTCAE v4.0	90 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum samples collected to determine AUC0-t	Blood samples will be collected to determine the serum concentrations of OPT101 (mg/kg)	90 days
Serum samples collected to determine Cmax	Blood samples will be collected to determine the serum concentrations of OPT101 (mg/kg)	90 days
Serum samples collected to determine CL/F	Blood samples will be collected to determine the serum concentrations of OPT101 (mg/kg)	90 days
Serum samples collected to determine t1/2	Blood samples will be collected to determine the serum concentrations of OPT101 (mg/kg)	90 days
Serum samples collected to determine HbA1C from baseline pre mixed meal tolerance test		90 days
Serum samples collected to determine c-peptide post mixed meal tolerance test		90 days
Serum samples collected to determine glucose levels (mmol/L) pre and post mixed meal tolerance test		90 days

Collaborators and Investigators

• Sponsor: Op-T LLC
• Investigators: Study Director: Lisa Boswell, MS, OP-T

Study record dates

Study Major Dates

• Study Start (Actual): September 27, 2022
• Primary Completion (Actual): February 21, 2024
• Study Completion (Actual): February 21, 2024

Study Registration Dates

• First Submitted: June 9, 2022
• First Submitted That Met QC Criteria: June 17, 2022
• First Posted (Actual): June 23, 2022

Study Record Updates

• Last Update Posted (Actual): May 3, 2024
• Last Update Submitted That Met QC Criteria: May 1, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1
• Other Study ID Numbers: OPT101-100-20

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No